Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04979806
Other study ID # W-5222-301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 28, 2022
Est. completion date May 2024

Study information

Verified date December 2023
Source Wockhardt
Contact Medical Monitor, MD
Phone 847-894-7392
Email clinicaltrials@mgp-online.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP. Approximately 528 hospitalized adult subjects (≥ 18 years of age) diagnosed with cUTI or AP will be enrolled in the study. The diagnosis of cUTI or AP will be based on a combination of clinical symptoms and signs plus the presence of pyuria. The total duration of treatment with study drug is 7 to 10 days. Each subject must remain hospitalized during the study drug treatment period; no outpatient parenteral antibiotic therapy is allowed.


Recruitment information / eligibility

Status Recruiting
Enrollment 528
Est. completion date May 2024
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female = 18 years of age 2. Provide a signed written informed consent prior to any study-specific procedures 3. Meet the clinical criteria for either cUTI or AP 4. Requires hospitalization to manage the cUTI or AP 5. Agrees to use effective methods of contraception Exclusion Criteria: 1. Known or suspected disease that may confound the assessment of efficacy. 2. Receipt of more than 72 hours of prior antibiotic therapy except for those failing prior antibiotic therapy and/or having documented uropathogen resistant to the prior therapy. 3. Rapidly progressive illness such that the subject is unlikely to survive the study period. 4. Pregnant or breastfeeding women 5. History of a seizure disorder requiring current treatment 6. Creatinine clearance < 15 mL/min or on renal dialysis 7. Neutropenia or elevated liver enzymes 8. Hypersensitivity to beta-lactam antibiotics 9. Unlikely to comply with the protocol or the Investigator considers that study participation may not be optimal for the subject

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cefepime-zidebactam (FEP-ZID)
3 g (2 g FEP + 1 g ZID) IV q8h
Meropenem
1 g IV q8h

Locations

Country Name City State
Bulgaria Dobrich Dobrich
Bulgaria Pleven Pleven
Bulgaria Plovdiv Plovdiv
Bulgaria Ruse Ruse
Bulgaria Silistra Silistra
Bulgaria Sofia Sofia
Bulgaria Varna Varna
China Changsha Changsha
China Changsha Changsha
China Changsha Changsha
China Chengdu Chengdu
China Chongqing Chongqing
China Liaoyang Liaoyang
China Shanghai Shanghai
Estonia Kohtla-Jarve Kohtla-Järve
Estonia Tallinn Tallin
Estonia Tallinn Tallinn
Estonia Tartu Tartu
Estonia Voru Võru
India Ahmedabad Ahmedabad Gujarat
India Bengaluru Bengaluru Karnataka
India Chandigarh Chandigarh Punjab
India Hisar Hisar Haryana
India Kolkata Kolkata West Bengal
India Nagpur Nagpur Maharashtra
India Surat Surat Gujarat
Lithuania Kaunas Kaunas
Lithuania Klaipeda Klaipeda
Lithuania Vilnius Vilnius
Lithuania Vilnius Vilnius
Lithuania Vilnius Vilnius
Mexico Chihuahua Chihuahua
Mexico Cuernavaca Cuernavaca
Mexico Guadalajara Guadalajara
Mexico Mérida Mérida
Mexico San Luis Potosí San Luis Potosí
Peru Cusco Cusco
Peru Iquitos Iquitos
Peru Lima Lima
Peru Lima Lima
Poland Boleslawiec Boleslawiec
Poland Krakow Krakow
Poland Lodz Lodz
Poland Ostroleka Ostroleka
United States Chula Vista Chula Vista California
United States St. Louis Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Wockhardt Medpace, Inc.

Countries where clinical trial is conducted

United States,  Bulgaria,  China,  Estonia,  India,  Lithuania,  Mexico,  Peru,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of subjects with overall success at Test-of-Cure Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to <1000 colony forming units or CFU/mL) Test Of Cure Visit (Day 17 ± 2 days)
Primary Percentage of subjects with Treatment-Emergent Adverse Events (TEAE) Collection of number of adverse events. Day 1 to the end of study Late Follow-Up visit (LFU) (26 ± 2 days)]
Secondary Percentage of subjects with overall success at End-of-Treatment Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (<1000 CFU/mL) End of Treatment Visit (Day 7 - 10 ± 1 day)
Secondary Percentage of subjects with clinical cure at End-of-Treatment Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to <1000 CFU/mL)(CFU)/mL. End of Treatment Visit (Day 7 - 10 ± 1 day)
Secondary Percent of subjects with microbiological eradication at End-of-Treatment Microbiologic eradication is defined as demonstrating <1000 CFU/mL of the bacterial pathogen found at study entry End of Treatment Visit (Day 7 - 10 ± 1 day)
Secondary Percentage of subjects with clinical cure at Test-of-Cure Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to <1000 CFU/mL) End of Treatment Visit (Day 17 ± 2 days)
Secondary Percent of subjects with microbiological eradication at Test-of-Cure Microbiologic eradication is defined as demonstrating <1000 CFU/mL of the bacterial End of Treatment Visit (Day 17 ± 2 days)
Secondary Percentage of subjects with clinical cure at Late Follow-up Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to <1000 CFU/mL) End of Treatment Visit (Day 26 ± 2 days)
Secondary Plasma Concentration of FEP-ZID On Days 1 and 3 of dosing prior to infusion, within 15 minutes after the end of infusion, and at 3 timepoints up to 7 hours hours post infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05905055 - P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales Phase 3
Not yet recruiting NCT05060419 - Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections Phase 2
Recruiting NCT02537847 - Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli Phase 2
Completed NCT02166476 - Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Phase 3
Completed NCT03757234 - IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis Phase 2
Completed NCT06141395 - NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification
Recruiting NCT05887908 - Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis Phase 3
Completed NCT02420366 - Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Recruiting NCT04654507 - Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children Phase 3
Completed NCT04686318 - Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis
Completed NCT04667195 - Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis
Completed NCT03788967 - Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Recruiting NCT05674032 - Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis
Completed NCT02168946 - Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Phase 3
Completed NCT01096849 - A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) Phase 2
Not yet recruiting NCT03630081 - Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3
Completed NCT03445195 - Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Phase 2
Completed NCT02486627 - A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) Phase 3
Completed NCT03477422 - CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria Phase 3
Recruiting NCT06059846 - A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Phase 3